Xalkori and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Xalkori (crizotinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Centrum Silver, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Heart attack when taking Xalkori. It is created by eHealthMe based on reports of 9,640 people who have side effects when taking Xalkori from the FDA, and is updated regularly.

What is Xalkori?

Xalkori has active ingredients of crizotinib. eHealthMe is studying from 9,659 Xalkori users. Check the latest studies of Xalkori.

What is Heart attack?

Heart attack is found to be associated with 2,489 drugs and 3,296 conditions by eHealthMe. Check the latest studies of Heart attack.

On Jul, 05, 2026

9,640 people reported to have side effects when taking Xalkori.
Among them, 34 people (0.35%) have Heart attack.

Among these 34 people:

How long have people been on Xalkori when they have Heart attack? *

What is the gender of people who have Heart attack when taking Xalkori? *

female: 23.33 %
male: 76.67 %

What is the age of people who have Heart attack when taking Xalkori? *

What are other drugs people take besides Xalkori? *

What are other side effects people have besides Heart attack? *

Neoplasm Progression (growth of tumour): 5 people, 14.71%
Nausea (feeling of having an urge to vomit): 4 people, 11.76%
Eye Disorder: 4 people, 11.76%
Abdominal Discomfort: 3 people, 8.82%
Liver Function Test Abnormal: 3 people, 8.82%
Oedema Peripheral (superficial swelling): 3 people, 8.82%
Electrocardiogram Qt Prolonged: 3 people, 8.82%
Pulmonary Oedema (fluid accumulation in the lungs): 3 people, 8.82%
Cardiac Arrest: 3 people, 8.82%
Cardiac Disorder: 3 people, 8.82%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 16 people, 47.06%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 11.76%
Visual Impairment: 3 people, 8.82%
Urinary Hesitation (difficulty in beginning the flow of urine): 3 people, 8.82%
Prostatomegaly (enlargement of the prostate): 3 people, 8.82%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 3 people, 8.82%
Cardiac Disorder: 2 people, 5.88%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 2.94%
Prostate Cancer: 1 person, 2.94%
Neoplasm Malignant (cancer tumour): 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Xalkori and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xalkori:

Xalkori (9,659 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Xalkori:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,489 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,296 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on crizotinib (the active ingredients of Xalkori) and Xalkori (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.